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Abstract 
Epigenetic regulation of gene expression is critical for normal development. Dysregulation of the 
epigenome can lead to the development and progression of a number of diseases relevant to 
paediatricians, including disorders of genomic imprinting and malignancies. It has long been 
recognised that early life events have implications for future disease risk, and epigenetic 
modifications may play a role in this, although further high-quality research is needed to better 
understand the underlying mechanisms. Research in the field of epigenetics will contribute to a 
greater understanding of growth, development and disease; however, paediatricians need to be able to 
interpret such research critically, in order to be able to utilise the potential advances brought about 
through epigenetic studies, whilst appreciating their limitations. 
 
 
Summary  
• Epigenetic regulation of gene expression is critical for normal development and disruption 
can result in disease 
 
• Diseases in which epigenetic dysregulation is known to occur include those involving 
genomic imprinting (e.g. Prader-Willi, Angelman, Beckwith-Wiedemann and Silver Russell 
syndromes), Rett syndrome and many malignancies. 
 
• Studies suggest epigenetic dysregulation is an important mediator in the Developmental 
Origins of Health and Disease (DOHaD) however further high-quality research is needed to 
better understand the underlying mechanisms.  
 
• An understanding of epigenetics will allow paediatricians to interpret research critically, 
embracing the potential advances brought about through epigenetic studies, whilst 
appreciating their limitations. 
 
  
What is meant by the term ‘epigenetics’? 
‘Epigenetics’ was a term coined by Conrad Waddington as the ‘branch of biology which studies the 
causal interactions between genes and their products, which bring the phenotype into being’. More 
recent definitions include a Cold Spring Harbor meeting consensus definition of ‘stably heritable 
phenotype resulting from changes in a chromosome without alterations in the DNA sequence’ and 
an NIH Roadmap Epigenomics Project definition of ‘both heritable changes in gene activity and 
expression…and also stable, long-term alterations in the transcriptional potential of a cell that are not 
necessarily heritable’. The lack of a clear, unifying definition means the term is commonly used to 
describe many processes which may affect gene function, in particular DNA methylation and histone 
modifications. 
 
DNA methylation: 
In mammals, DNA methylation typically involves the addition of a methyl group to the 5’carbon of 
cytosine residues (5-methylcytosine; 5mC) in a cytosine-phosphate-guanine (CpG) sequence. ‘CpG 
islands’ are regions of the genome that contain a large number of CpG dinucleotides which are 
common near the transcription start site of genes and are generally unmethylated. In differentiated 
cells, DNA methylation patterns associate with gene silencing or activation, however there is ongoing 
debate over the extent to which DNA methylation drives changes in gene transcription as opposed to 
reflecting transcriptional changes driven by the actions of transcription factors.1 Although not fully 
understood, DNA methylation is thought to have an important role in development and cellular 
differentiation, for example, in silencing germline genes in somatic cells. Furthermore, DNA 
methylation plays an important role in genomic imprinting, X-inactivation and in silencing 
transposable elements, which make up a large fraction of the genome. 
 
Histone modifications: 
DNA is packaged around histone proteins in a complex known as chromatin. Post-translational 
histone modifications (e.g. methylation, acetylation, phosphorylation) are important in many 
biological processes such as gene regulation, DNA repair and chromatin condensation. In general, 
DNA that encodes actively transcribed genes is more loosely packaged (euchromatin) while DNA 
encoding inactive genes is more tightly condensed (heterochromatin). 
 
The epigenome and paediatric disease 
Epigenetic regulation of gene expression is critical for normal development and disruption can result 
in disease.2 There are several examples of paediatric diseases in which perturbations of epigenetic 
processes have been described.  
 
a) Imprinting disorders 
Most autosomal genes display bi-allelic expression and are expressed equally from maternal and 
paternal alleles. Imprinted genes display mono-allelic expression; at these genes, either the maternal 
or paternal allele is silenced during germ cell development, predominantly by DNA methylation.3 
Imprinted genes are normally arranged in clusters and regulated by common imprinting control 
regions (ICRs) which are differentially methylated dependent upon which parent the gene is inherited 
from.3 Genomic imprinting is essential for normal growth and development, however any 
genetic/epigenetic alteration resulting in downregulation or loss of function of the active allele could 
have significant consequences, as there is no other active allele to compensate. The imprinting 
disorders primarily involve problems with growth or neurological development. 
 
There are several different mechanisms leading to an increase or decrease in the dose of imprinted 
genes: (i) genetic abnormalities affecting the expressed allele e.g. mutations, deletions or duplications; 
(ii) chromosomal errors resulting in the re-organisation of genetic material e.g. translocations and 
uniparental disomy; and (iii) epigenetic errors affecting DNA methylation of differentially methylated 
regions controlling the expression of imprinted genes, in some cases due to an underlying genetic 
abnormality. Thus, although these conditions are associated with epigenetic dysregulation, the 
majority occur as a consequence of genetic abnormalities. 
 
Angelman and Prader-Willi syndromes 
Angelman (AS) and Prader-Willi (PWS) syndromes are perhaps the most well-known imprinting 
disorders, both caused by functional loss of genes located in the same region of chromosome 15.2 AS 
is characterised by cognitive impairment, developmental delay, speech impairment and epilepsy.3 
70% of cases result from deletion of a region in the maternal chromosome 15, which contains 
UBE3A, a gene in the ubiquitin pathway which, in the developing brain, is usually maternally-
expressed and paternally-silenced. Less common causes include mutations in the maternally inherited 
gene, uniparental disomy (where both chromosome 15s are inherited from the father), and imprinting 
defects, whereby the maternal gene is also silenced. Common to all cases is the loss of expression of 
maternal UBE3A, with an inability to compensate for this due to the normal silencing of the paternal 
allele. PWS is phenotypically very different, presenting with hypotonia, delayed development, 
behavioural problems, hyperphagia and obesity3 resulting from loss of the normally expressed 
paternal copies of genes in the same region of chromosome 15, as a consequence of deletion, mutation 
or uniparental disomy. Again there is an inability to compensate for the lack of gene expression from 
the paternal alleles because the maternal copies are silenced.   
 
Beckwith-Wiedemann and Silver-Russell Syndrome 
Precise epigenetic regulation of gene expression provides fine-tuning of growth signals. Paternally-
expressed genes tend to be growth-promoting, whilst maternally-expressed genes tend to growth-
restrict.3 Beckwith-Wiedemann syndrome (BWS) is an overgrowth disorder characterised by 
macrosomia, macroglossia, abdominal wall defects and an increased risk of embryonal tumours. BWS 
is a clinically heterogeneous condition which highlights the complexity of epigenetic regulation of 
growth; the condition can be caused by several different mechanisms, all affecting genes important 
for growth regulation in the imprinted region of chromosome 11p15.  
 
This imprinted region is functionally divided into two domains, each of which has a different ICR 
(Figure 1). ICR1 regulates expression of IGF2, a growth-promoting gene, and H19, a non-coding 
RNA (ncRNA). ICR1 is normally methylated on the paternal allele, and unmethylated on the maternal 
allele leading to paternal IGF2 expression and maternal H19 expression. In contrast, ICR2 is 
methylated on the maternal allele and regulates expression of several genes, including CDKN1C, a 
negative regulator of cell proliferation. Hypomethylation of ICR2 on the maternal allele (the most 
common epigenetic alteration in BWS) results in reduced CDKN1C expression. BWS can also be 
caused by mutations in CDKN1C, or through gain of methylation at maternal ICR1 resulting in 
biallelic expression of IGF2 and biallelic silencing of H19. A small proportion of cases are caused by 
paternal uniparental disomy. This deeper understanding of the causative mechanisms of BWS can 
assist with predicting clinical features, as different genetic and epigenetic alterations are associated 
with specific phenotypes, including differing relative risks of tumour development.5 
 
Interestingly, loss of methylation of ICR1 on the paternal allele, resulting in biallelic silencing of 
IGF2, causes the clinical condition known as Silver-Russell syndrome (SRS). Children with SRS have 
impaired growth, including reduced birthweight, failure to thrive, short stature and distinct facial 
features. SRS can also be caused by maternal uniparental disomy of chromosome 7 although the 
mechanism by which this results in the same phenotype as epigenetic changes in ICR1 on 
chromosome 11 remains unknown.4 A greater understanding of these disorders and the associated 
epigenetic dysregulation is likely to contribute to new knowledge of the mechanisms underpinning 
normal growth and development.  
 
b) Rett syndrome 
Rett syndrome is a severe neurological disorder caused by a mutation in the X-linked gene Methyl-
CpG-binding protein 2 (MECP2).5 6 It is inherited in an X-linked dominant pattern and is therefore 
typically only seen in girls, as MECP2 mutation is lethal in hemizygous males. Rett syndrome is 
characterised by normal growth and development for the first 6-18 months, followed by 
developmental slowing and loss of motor skills and speech. Affected girls also display gait 
abnormalities, stereotypical hand movements, seizures and intellectual disability.6 The role of the 
epigenome can be seen two-fold in this syndrome: firstly, epigenetic processes account for at least 
part of the considerable phenotypic variability amongst patients with Rett syndrome, through the 
normal biological process of X-inactivation. In females, one X-chromosome is silenced by DNA 
methylation, a process which usually occurs randomly in any cell. Thus, the abnormal X-chromosome 
should be silenced in ~50% of cells. However, X-inactivation can sometimes display skewing, 
resulting in a greater or lesser proportion of cells with the abnormal X-chromosome being active, 
resulting in a more or less severe phenotype.6 Secondly, unlike the imprinting disorders, the mutation 
affects a protein predicted to have epigenetic properties: MECP2 encodes methyl CpG binding protein 
2 which binds to methylated DNA, essentially “reading” the epigenetic code and regulating gene 
transcription.6 The protein is expressed particularly highly in the brain and is important for 
maintaining neuronal function.7 The neurological phenotype in MECP2-null mice can be reversed by 
re-expression of MECP2 after birth, highlighting the reversible nature of epigenetic changes and the 
promise of future therapeutic strategies for disorders such as Rett syndrome.6 7  
 
c) Cancer 
In the disorders discussed thus far we have seen that epigenetics plays an important role in growth and 
development, and so it is perhaps unsurprising that epigenetic dysregulation is also seen in cancer - a 
disease in which normal developmental programs are disordered and there is uncontrolled cell 
proliferation. Altered DNA methylation is a hallmark of human cancers – including both global DNA 
hypomethylation and CpG island hypermethylation.8 DNA hypomethylation of oncogenes could 
result in their increased expression, whilst promoter CpG island hypermethylation often results in 
silencing of the associated gene, which may be of particular importance in the context of tumour 
suppressor genes.2 For example, DNA methylation changes occur in human gliomas, with some 
studies showing CpG island hypermethylation in a subset of gliomas. A ‘CpG island methylator 
phenotype’ (CIMP) resulting in cancer-specific CpG island hypermethylation has been described in a 
in a subset of cancers including gliomas. Notably, the CIMP occurs as a consequence of gene 
mutations, for example mutations in the genes isocitrate dehydrogenase type 1 (IDH1) and BRAF (a 
proto-oncogene encoding for the B-Raf protein) have been described in association with CIMP in a 
subset of gliomas.8 9 
 
Our knowledge of the role of histone modifications in controlling gene expression and contributing to 
oncogenesis has increased dramatically over recent years. This is clearly demonstrated in paediatric 
high-grade gliomas (HGGs), which account for around half of paediatric gliomas, themselves the 
most common type of paediatric brain tumour.10 Although many oncological disorders of childhood 
have seen significant improvements in survival rates over recent years, children with HGGs continue 
to have very poor outcomes with 2-year survival ranging from 10-30%.11 Recent analysis of paediatric 
HGGs has identified genetic mutations in histone 3 variants, which result in disruption of the 
epigenetic post-translational modification of histones. Importantly, distinct mutations affecting 
modifications at separate sites on the histone tail associate with the neuroanatomical site of the 
tumours, effectively dividing patients into subgroups, with differing demographics, response to 
treatment and prognosis.11 Furthermore, these mutations are not seen in adult HGGs, suggesting that 
the mechanisms of tumorigenesis in adult and paediatric HGGs are molecularly distinct.11  
 
This increased awareness and understanding of the complex interplay between genetic and epigenetic 
dysregulation in paediatric cancers has implications for treatment, as it opens the door for novel 
therapeutic strategies, particularly targeting the epigenome. The dynamic nature and potential 
reversibility of epigenetic modifications makes epigenetic therapies an attractive proposition, indeed a 
number of drugs affecting histone modifications are already in clinical trials for paediatric gliomas,12 
and epigenetic therapies are already successfully used in the treatment of other malignancies.13 
 
Epigenetics and the Developmental Origins of Health and Disease (DOHaD) 
Numerous studies in humans and in animal models have demonstrated that exposure to adverse 
environmental conditions in utero or in early postnatal life increases the risk of cardio-metabolic, 
neurobehavioural and reproductive disorders in adulthood.13 Adverse early life experiences include 
prenatal and early postnatal factors e.g. under- or overnutrition, glucocorticoid overexposure or being 
born preterm.14 15 The dynamic nature of the epigenome may enable an organism to respond and adapt 
to environmental influences, and epigenetic modifications may provide a mechanism by which rapid 
and reversible phenotypic changes can be achieved.16 Many animal and human studies have reported 
that early life environmental factors associate with alterations in DNA methylation, histone 
modification and/or ncRNA (reviewed in 17). This is distinct from the previous examples, since it 
represents a purely non-mutational mechanism of disease susceptibility. However, although the 
substantial amount of interest in the area means that it is now almost accepted that the early life 
environment influences long-term health through induced changes in epigenetic marks during 
development, it is important to note that there is a general lack of mechanistic evidence.  
 
Examples of human studies suggesting a role for the epigenome include those showing that 
individuals exposed to famine in utero during the Dutch Hunger Winter have altered DNA 
methylation at IGF2 and a number of other metabolic genes when compared with their unexposed 
same-sex siblings.18 19 Maternal consumption of an unbalanced diet associates with changes in DNA 
methylation in the offspring in adulthood.20 Exposure to maternal obesity and/or gestational diabetes 
is associated with an increased risk of obesity and diabetes in the offspring, and changes in DNA 
methylation have been reported in individuals in these studies.21 Individuals born preterm are at 
higher risk of neurodevelopmental disorders22 and we have demonstrated alterations in DNA 
methylation at sites relevant to neurodevelopment in preterm infants in comparison to term born 
controls.23 In order to further explore the role of the epigenome in the programming of disease risk, 
animal models have been developed. These include manipulations of maternal diet (including under- 
or overnutrition),24 prenatal glucocorticoid overexposure25 or exposure to environmental toxins or 
‘endocrine disrupting chemicals’26 in species as diverse as rodents, sheep and non-human primates. 
Work in such models has described effects on many organ systems in association with changes in 
DNA methylation and histone modifications at genes important in development and function 
(reviewed in 27).    
 
Epidemiological data and animal studies have also shown that programmed effects are not limited to 
the first-generation offspring (i.e. those directly exposed to an insult), but can be transmitted to 
subsequent generations through non-genomic mechanisms. Reports describing alterations in DNA 
methylation, histone modifications and/or ncRNAs in the germline suggest a role for 
‘transgenerational epigenetic inheritance’ in the transmission of disease risk. However, while 
epigenetic inheritance does occur in plants and in the nematode worm, C. elegans, the evidence for 
transgenerational epigenetic inheritance in mammals remains limited. Further studies are necessary to 
understand whether (and how) induced alterations in the germline epigenome escape the extensive 
epigenetic reprogramming which occurs in the germline and post-fertilisation embryo and to 
understand the mechanisms by which alterations in germ cells lead to the reproduction of the 
programmed effects in subsequent generations.  
 
Interpreting epigenetic studies in humans 
The specific disorders discussed at the start of the review (e.g. imprinting disorders, Rett syndrome 
and cancers) involve large changes in the epigenome (e.g. complete loss or gain of DNA 
methylation), generally occur as a consequence of genetic abnormalities, and are supported by 
detailed mechanistic studies. In contrast, most clinical studies of relevance to paediatrics, particularly 
those in the DOHaD field (and the associated animal studies), are largely descriptive and usually 
report very small changes in DNA methylation. Although these studies are often cited as suggesting a 
causal link between changes in DNA methylation and disease, in reality many of the findings are of 
uncertain significance. In order to prove causality i.e. to show that epigenetic differences (i) are a 
consequence of the insult (ii) affect gene regulation in the tissue of interest and (iii) impact on disease 
risk, more detailed functional studies are necessary, and these are generally lacking. In this section we 
review some of the other common problems with population-level epigenetic research and discuss 
factors to consider when interpreting DNA methylation studies in particular. 
 
Study design 
In observational studies, recruitment bias can mean that even with carefully chosen control 
populations and correction for confounders, the influence of additional socio-economic/environmental 
factors is missed. Many epigenome-wide association studies (EWAS) in human populations are 
limited by their small sample size – indeed, given the normal variability in DNA methylation between 
individuals, many (perhaps most) are underpowered. Additionally, studies are frequently confounded 
by multiple comparisons, making it likely that erroneous inferences are made.  
 
Which samples to profile? 
In human studies, particularly in children, DNA may only be available from accessible tissues e.g. 
placenta, buccal cells or blood. However, since DNA methylation and histone modification patterns 
are highly tissue-specific, methylation/histone marks in one tissue are unlikely to be a good proxy for 
those present in other, more inaccessible tissues.28 29 Some studies have attempted to address this e.g. 
by profiling DNA methylation in both blood and post mortem tissue and have shown that although 
there are some similarities, there are also many differences between tissues, suggesting that blood-
based profiling may provide only limited information about underlying pathology elsewhere.29 30 
Nevertheless, the use of accessible tissues may still be useful for biomarker identification, although 
this requires the development of robust algorithms, since many of the changes described are small, 
and replication in other cohorts is essential. 
 
A key confounder in many studies is that tissues and blood are comprised of a mix of different cell 
types, and alterations in the proportions of different cells (which will have different DNA methylation 
profiles) will affect the percentage DNA methylation found in any tissue or in blood.31 In other words, 
measurable differences in DNA methylation may simply reflect differences in cell/tissue composition 
(Figure 2). Lifestyle choices or the development of disease may impact on cell-type distribution - for 
example, changes in blood cell composition occur with smoking or diabetes. Most population-based 
DNA methylation studies report small differences in DNA methylation (typically ~5%) and rarely 
assess whether this represents a change in DNA methylation in a single cell type, or differences in the 
cellular population. Further, differences in cell-subtype populations between individuals may be a 
major confounder in many studies.  
 
Genetic differences are important 
Up to 80% of inter-individual differences in DNA methylation can be attributed to DNA sequence 
polymorphisms,32 i.e. underlying genetic differences result in inter-individual differences in DNA 
methylation profiles. Where such genetic differences are also important in disease risk, this could 
result in the assumption that the disease occurred as a result of changes in DNA methylation, rather 
than as a result of differences in the DNA sequence itself (Figure 3). To make it more complicated, 
DNA methylation differences may also be a consequence of inter-individual differences in gene 
expression. To fully address both of these issues, additional analyses require profiling of both the 
genome and gene expression. 
 
Cause or consequence? 
It is also important to consider the phenomenon of ‘reverse causation’, where the disease itself leads 
to changes in DNA methylation rather than vice versa, such that the changes in the epigenome are a 
consequence rather than a cause of disease (Figure 3). This is particularly the case for cross-sectional 
studies, for example although studies report differences in DNA methylation at the HIF3A gene in 
obese individuals, a recent analysis suggests that rather than there being a causal effect of HIF3A 
methylation on body mass index, instead, obesity affects HIF3A methylation.33 Reverse causation is 
impossible to exclude in studies only performed in adults exposed to an adverse early life 
environment, including the Dutch Famine or Motherwell cohorts.19 20 Longitudinal studies are 
therefore important to understand the chronology of changes and assist in the identification of 
biomarkers of risk. 
 
Summary 
In conclusion, it is clear that dysregulation of the epigenome occurs in a number of paediatric 
diseases. Expanding our knowledge of these disease processes in turn contributes to a greater 
understanding of normal growth and development. It has long been recognised that early life events 
have implications for future disease risk, and although studies suggest this may at least in part be 
mediated by epigenetic modifications; further high-quality research is needed to better understand the 
underlying mechanisms. A working knowledge of epigenetics will allow paediatricians to interpret 
such research critically, embracing the potential advances brought about through epigenetic studies, 
whilst appreciating their limitations. 
 
Most importantly, building a strong foundation in epigenetic research will allow paediatricians to take 
part in the conversations that will undoubtedly become part of our future clinical practice, as we begin 
to apply this knowledge to risk stratify patients and move towards more personalised medicine. As an 
increasing number of epigenetic therapies are developed, it will be essential for paediatricians to 
understand their mechanisms and their role in treating disease, in order to select the most appropriate 
therapies for each individual patient. 
 
 
 
  
Figure Legends 
 
Figure 1: Imprinted regions of chromosome 11p15.5. (P=paternal allele, M=maternal allele. Red = 
silenced gene. Green = active gene. Filled hexagon = methylated DNA, unfilled hexagon = 
unmethylated DNA). A) Normal methylation pattern - ICR1 is methylated on the paternal allele and 
unmethylated on the maternal allele, resulting in paternal expression of IGF2 and maternal expression 
of H19. ICR2 is methylated on the maternal allele and unmethylated on the paternal allele resulting in 
maternal expression of CDKN1C. B & C) Two causes of BWS – B) Loss of methylation at ICR2 on 
the maternal allele resulting in reduced expression of CDKN1C. C) Gain of methylation at ICR1 on 
the maternal allele resulting in bi-allelic expression of IGF2. D) One cause of SRS – Loss of 
methylation at ICR1 on the paternal allele resulting in bi-allelic expression of H19.  
 
Figure 2: Interpreting changes in DNA methylation in mixed cell populations. Tissues and blood are 
comprised of a mix of different cell types and individual cell types have different methylation 
profiles. A) Schematic diagram of a tissue comprising a mixed cell population (four cell types 
indicated by circles, squares, triangles and pentagon). One specific CpG site is normally methylated in 
the square cells (filled) whereas it is unmethylated in the other cell types (open), giving a % DNA 
methylation of 25% when the whole tissue is profiled. B) Following exposure to an ‘insult’, the CpG 
also becomes methylated in a proportion of the circular cells such that profiling gives a % methylation 
of 40% at that locus. C) The same result is also seen when rather than changing DNA methylation 
within a cell type, exposure to an insult instead results in a change in cellular population.   
 
Figure 3: Interpreting changes in DNA methylation cause versus consequence. A) Although the 
results of many studies have been used to suggest that changes in DNA methylation cause disease, 
there have been very few mechanistic studies to support this. B) Spurious associations can arise when 
a third factor leads to both a change in DNA methylation and the disease. Up to 80% of inter-
individual differences in DNA methylation can be attributed to DNA sequence polymorphisms i.e. 
underlying genetic differences result in inter-individual differences in DNA methylation profiles. 
Where such genetic differences are also important in disease risk, this could result in the assumption 
that the disease occurred as a result of changes in DNA methylation, rather than as a result of 
differences in the DNA sequence itself. C) Disease states may lead to changes in DNA methylation 
rather than vice versa - a phenomenon termed reverse causation.  
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